Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 2/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.39 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3900906 | 0.91 | NR3C2 (0.46) | CYP17A1IGF1RCCR2NR3C2RIOK2 | |
| SCHEMBL5202372 | 0.89 | NR3C2 (0.47) | CYP17A1IGF1RCCR2NR3C2RIOK2 | |
| SCHEMBL3892526 | 0.88 | CCR2 (0.47) | IGF1RCCR2ATRLOXL2 | |
| SCHEMBL3888179 | 0.88 | NR3C2 (0.46) | CYP17A1IGF1RCCR2NR3C2RIOK2 | |
| SCHEMBL3892560 | 0.87 | NR3C2 (0.51) | IGF1RNR3C2RIOK2 | |
| SCHEMBL3894787 | 0.87 | IGF1R (0.42) | CYP17A1IGF1RCCR2NR3C2RIOK2 | |
| SCHEMBL3887366 | 0.86 | IGF1R (0.47) | CYP17A1IGF1RCCR2NR3C2RIOK2 | |
| SCHEMBL3890118 | 0.86 | NR3C2 (0.42) | CYP17A1IGF1RCCR2NR3C2RIOK2 | |
| SCHEMBL3890052 | 0.84 | NR3C2 (0.48) | IGF1RCCR2NR3C2RIOK2 | |
| SCHEMBL5356933 | 0.84 | IGF1R (0.43) | CYP17A1IGF1RCCR2NR3C2RIOK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414443-B1 | BENZIMIDAZO 4,5-f|ISOQUINOLINONE DERIVATIVES | MERCK & CO INC (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1414443-A4 | BENZIMIDAZO 4,5-f]ISOQUINOLINONE DERIVATIVES | MERCK & CO INC (US) | 2005-05-11 | — | — | EP | disclosed |
| US-6852727-B2 | Benzimisazo[4,5-f]isoquinolinone derivatives | MERCK & CO., INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040176601-A1 | Benzimisazo[4,5-f]isoquinolinone derivatives | MERCK SHARP & DOHME LLC | 2004-09-09 | — | — | US | disclosed |
| EP-1414443-A1 | BENZIMIDAZO 4,5-f]ISOQUINOLINONE DERIVATIVES | Merck & Co., Inc. (US) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003011285-A1 | BENZIMIDAZO[4,5-f]ISOQUINOLINONE DERIVATIVES | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176601-A1 | Benzimisazo[4,5-f]isoquinolinone derivatives | JAK1, JAK3, JAK2 | CYP17A1 2604/4885IGF1R 1309/4885CCR2 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.